Skip to content

Transform millions of lives with a groundbreaking drug

Become an early investor in disease-targeting therapies for obesity, liver disease, chronic inflammation, and more indications.

Corporate Profile

MetaShape Pharma is a pre-clinical stage pharmaceutical company dedicated to discovering and developing transformative drugs for white fat-related diseases. Our team is deeply immersed in the field of pharmacology, with a wealth of experience in medicine and PNP inhibitors. We understand the complex challenges patients face when dealing with these diseases, and we are committed to creating differentiated treatments that can help improve their lives.

With our extensive knowledge of pharmacology and our innovative approach to the treatment of high-prevalence diseases, we are exploring new pathways to create drugs with the potential to make a meaningful impact. Our team is united by a shared passion to work towards a goal that is bigger than ourselves, and we are driven to study and deliver medicines that can offer significant benefits to those living with fat-related diseases. Whether it’s obesity, liver disease, chronic inflammation, or other related conditions, our ultimate aim is to provide effective treatments that can make a difference in the lives of our patients.

OBESITY

Breaking the Cycle.

OBESITY

Breaking the Cycle.

Treating the Root Cause of Obesity with a New Solution

Other options on the market have failed to treat the root cause of obesity. From supplements to weight loss products to liposuction, the market is desperate for a sustainable solution to treat obesity.

root cause of obesity

We’re reprogramming white fat to burn energy,
not store it.

MetaShape holds a worldwide, exclusive license to the new patents of MS 001 from Laevoroc Immunology for development in non-cancer indications.

Invest Confidently with Risk-Mitigated Pathways

We’re not just looking at obesity. Our Mechanism of Action has application in additional indications.

Obesity

Invest Confidently with Risk-Mitigated Pathways

Immune-Mediated Disease

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Lower Urinary Tract Dysfunction

Cancer-Related Obesity

Impact Statement

MS 001, proven to be safe in patients, will allow us to treat silent killers like obesity, liver disease, and other chronic conditions, helping millions of people live healthier lives, while also decreasing the healthcare burden for both families and society as a whole.

Request Our One-Pager

MetaShape’s Trajectory and 5-Year Development Plan

Impact Statement

MS 001, proven to be safe in patients, will allow us to treat silent killers like obesity, liver disease, and other chronic conditions, helping millions of people live healthier lives, while also decreasing the healthcare burden for both families and society as a whole.

Request Our One-Pager

MetaShape’s Trajectory and 5-Year Development Plan

Join us in this
exciting discovery

Top